Internists, PCPs, nurses, pharmacists, NPs, and PAs involved in the management of patients with T2DM
Type 2 Diabetes, GLP 1 agonist, Hypoglycemia, Weight, Injectable, Exenatide, Exenatide QW, Albiglutide, Liraglutide, Cardiovascular Risk
Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists
Program Overview/Statement of Need:
The most recent State of Health Care Quality Report, published by the National Committee for Quality Assurance (NCQA), indicated that only 43.2% of patients with diabetes had good HbA1c control (<7%), while 61.3% had an HbA1c of <8% and 28.5% had poor control (HbA1c >9%). Additional data show that many patients who reach their glycemic goal do not maintain it. Patients must become "partners in care," but more direction is needed to help clinicians successfully engage their patients.
Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists will guide internists, PCPs, nurses, pharmacists, NPs, and PAs through the practical application of up-to-date information in T2DM management and best practices to break down barriers preventing patients from reaching HbA1c goals. Clinicians will gain an improved understanding of the place of GLP-1 agonists in the treatment armamentarium; will be better able to differentiate the GLP-1 agonists currently available, including safety and efficacy profiles and injection delivery methods.
Target Audience: This activity is intended for internists, PCPs, nurses, pharmacists, NPs, and PAs involved in the management of patients with T2DM.
After completion of this activity, participants should be able to:
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.
|Supported Phones & Tablets: |
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above